OncoMatch/Clinical Trials/NCT07003542
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
Is NCT07003542 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Sitagliptin for glioblastoma.
Treatment: Sitagliptin — The purpose of this study is to evaluate whether treating glioblastoma patients with sitagliptin can improve immune response against the tumor by targeting specific immune cells called myeloid-derived suppressor cells (MDSCs) that suppress your body's natural immune response against cancer. Sitagliptin is an investigational drug for this condition that works by inhibiting an enzyme called dipeptidyl peptidase 4 (DPP-4), which MDSCs rely on to enter the brain and function. While sitagliptin is FDA-approved for diabetes treatment, its use in glioblastoma is investigational (experimental).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Disease stage
Required: Stage WHO GRADE 4 (WHO)
Grade: 4 (WHO)
WHO grade 4 glioma (including tumors with molecularly defined grade 4 astrocytoma)
Prior therapy
Cannot have received: gliptin (sitagliptin)
Participants must not have received sitagliptin or other gliptins.
Cannot have received: investigational agent
Participants receiving any other investigational agents.
Lab requirements
Blood counts
Hemoglobin ≥ 9 g/dl; Absolute neutrophil count ≥ 1,500/mcL; Platelet count ≥ 100,000/mcL
Kidney function
Calculated creatinine clearance > 50 mL/min or creatinine < 1.5x institutional ULN
Liver function
Total bilirubin < 1.5x institutional ULN; AST (SGOT) ≤ 3x institutional ULN; ALT (SGPT) ≤ 3x institutional ULN
adequate organ function and laboratory parameters within 21 days of study entry as defined below
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07003542 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gliptin, investigational agent disqualifies patients from enrollment.
What disease stage is eligible?
Stage WHO GRADE 4 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages